Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.64 |
| ▸ | GSR | P00390 | 2/20 | 0.80 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.64 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.58 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.53 |
| ▸ | ARG2 | P78540 | 4/20 | 0.50 |
| ▸ | ARG1 | P05089 | 3/20 | 0.50 |
| ▸ | NOS2 | P35228 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.43 |
| ▸ | GRM6 | O15303 | 1/20 | 0.43 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL23648486 | 1.00 | GSR (0.80) | GSRPTGS1SLC7A11CPB2RNPEP | |
| Lysine SCHEMBL1535094 | 1.00 | GSR (0.80) | GSRPTGS1SLC7A11CPB2RNPEP | |
| Lysine SCHEMBL29037480 | 1.00 | GSR (0.80) | GSRPTGS1SLC7A11CPB2RNPEP | |
| Lysine SCHEMBL23648487 | 1.00 | GSR (0.80) | GSRPTGS1SLC7A11CPB2RNPEP | |
| Lysine SCHEMBL4272062 | 1.00 | GSR (0.80) | GSRPTGS1SLC7A11CPB2RNPEP | |
| Lysine SCHEMBL22654501 | 0.94 | GSR (0.71) | GSRPTGS1SLC7A11CPB2RNPEP | |
| Ornithine Aketoglutarate SCHEMBL1696575 | 0.94 | GSR (0.69) | GSRPTGS1SLC7A11CPB2RNPEP | |
| Ornithine SCHEMBL1696576 | 0.94 | GSR (0.69) | GSRPTGS1SLC7A11CPB2RNPEP | |
| Lysine SCHEMBL3882926 | 0.93 | GSR (0.69) | GSRPTGS1SLC7A11CPB2RNPEP | |
| Lysine SCHEMBL3496042 | 0.93 | GSR (0.69) | GSRPTGS1SLC7A11CPB2RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233073-A1 | COMPOUND FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 | Universitat De València, Estudi General (ES) | 2017-10-25 | — | — | EP | claimed |
| WO-2016097299-A1 | COMPOUND FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 | UNIVERSITAT DE VALÈNCIA, ESTUDI GENERAL (ES) | 2016-06-23 | — | — | WO | claimed |
| US-20180263943-A1 | COMPOUND FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 | UNIVERSITAT DE VALÈNCIA, ESTUDI GENERAL (ES) | 2018-09-20 | — | — | US | disclosed |
| EP-3233073-A1 | COMPOUND FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 | Universitat De València, Estudi General (ES) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097299-A1 | COMPOUND FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 | UNIVERSITAT DE VALÈNCIA, ESTUDI GENERAL (ES) | 2016-06-23 | — | — | WO | disclosed |
| EP-3034074-A1 | Compound for treatment of myotonic dystrophy type 1 | Universitat De València, Estudi General (ES) | 2016-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263943-A1 | COMPOUND FOR TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 | MBNL1, SMN1; SMN2, SQSTM1 | PTGS1 2737/4885GSR 3340/4885SLC7A11 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.